

HEMOCOMPATIBILITY DETERMINATION STUDY

for the InVision-Plus® Neutral Advantage Technology

Table 1: Hemolytic Parameters

Hemolytic Index	Results
InVision-Plus® Neutral Advantage Technology	0.00 % Non-Hemolytic
Negative Control	0.40 %
Hemolytic Index above the Negative Control	Hemolytic Grade
0.0% - 2.0%	Non-Hemolytic
2.0% - 5.0%	Slightly Hemolytic
Above 5.0%	Hemolytic

Table 2: Hematological Parameters

Mean	InVision-Plus® Neutral Advantage Technology	Unexposed Negative Control	P-Value*
WBC	4.20 K/microliter	4.15 K/microliter	0.656
RBC	4.20 M/microliter	4.22 M/microliter	0.829
HgB	12.60 g/dL	12.80 g/dL	0.573
Hct	36.40 %	36.50 %	0.944
MCV	86.80 fL	86.50 fL	0.072
MCH	30.10 pg	30.30 pg	0.253
MCHC	34.70 g/dL	35.10 g/dL	0.129
RDW	13.70 %	13.70 %	0.731
PLT	45.00 K/microliter	44.00 K/microliter	0.799
MPV	9.97 fL	9.60 fL	0.290

* The ANOVA analysis was performed by comparing all three device replicates with all the unexposed negative control replicates. A p-value > 0.05 indicates similarity and a p-value <0.05 indicates a difference.

WBC (White Blood Cell Count)

RBC (Red Blood Cell Count)

HgB (Hemoglobin)

Hct (Hematocrit)

MCV (Mean Corpuscular Volume)

MCH (Mean Corpuscular Hemoglobin)

MCHC (Mean Corpuscular Hemoglobin Concentration)

RDW (Red Cell Distribution Width)

PLT (Platelet Count)

MPV (Mean Platelet Volume)



RyMed
TECHNOLOGIES, LLC

InVision-Plus® is a registered trademark of RyMed Technologies, LLC
U.S. Patent Numbers: 6,113,068; 6,299,131; 6,994,315; 7,530,546 B2; 8,096,525 B2,
and other U.S. and foreign patents pending © 2014 Rymed Technologies, LLC